Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanlin Yin

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal for Immunotherapy of Cancer|January 5, 2023
Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinomaQiangda Chen, Hanlin Yin, Siyao Liu, et al.
Annals of the Rheumatic Diseases|December 19, 2025
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multiomics analysisWanyi Lin, Zhangyi Zhao, Chenhan Jia, et al.
Cancer Letters|June 25, 2019
Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathwayNing Pu, Shanshan Gao, Hanlin Yin, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Poor clinical outcomes and immunoevasive contexture in CD161<sup>+</sup>CD8<sup>+</sup> T cells barren human pancreatic cancerQiangda Chen, Hanlin Yin, Zhenlai Jiang, et al.
Therapeutic Advances in Medical Oncology|September 25, 2020
Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70Shanshan Gao, Ning Pu, Hanlin Yin, et al.
Iscience|March 10, 2025
Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohortsHaokang Feng, Zhixue Chen, Jianang Li, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2026
Integrated Clinical and Proteomic Profiling of CD19 CAR-T Cell Therapy in Progressive Systemic SclerosisChenhan Jia, Wanyi Lin, Zhangyi Zhao, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 25, 2023
Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic SclerosisHanlin Yin, Oliver Distler, Lichong Shen, et al.
International Journal of Surgery (London, England)|June 11, 2025
Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pancreatic cancer after surgical resection: a cohort studyNing Pu, Qiangda Chen, Jiande Han, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 17, 2025
The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic CancerJiande Han, Hanlin Yin, Taochen He, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal for Immunotherapy of Cancer|January 5, 2023
Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinomaQiangda Chen, Hanlin Yin, Siyao Liu, et al.
Annals of the Rheumatic Diseases|December 19, 2025
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multiomics analysisWanyi Lin, Zhangyi Zhao, Chenhan Jia, et al.
Cancer Letters|June 25, 2019
Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathwayNing Pu, Shanshan Gao, Hanlin Yin, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Poor clinical outcomes and immunoevasive contexture in CD161<sup>+</sup>CD8<sup>+</sup> T cells barren human pancreatic cancerQiangda Chen, Hanlin Yin, Zhenlai Jiang, et al.
Therapeutic Advances in Medical Oncology|September 25, 2020
Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70Shanshan Gao, Ning Pu, Hanlin Yin, et al.
Iscience|March 10, 2025
Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohortsHaokang Feng, Zhixue Chen, Jianang Li, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2026
Integrated Clinical and Proteomic Profiling of CD19 CAR-T Cell Therapy in Progressive Systemic SclerosisChenhan Jia, Wanyi Lin, Zhangyi Zhao, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 25, 2023
Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic SclerosisHanlin Yin, Oliver Distler, Lichong Shen, et al.
International Journal of Surgery (London, England)|June 11, 2025
Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pancreatic cancer after surgical resection: a cohort studyNing Pu, Qiangda Chen, Jiande Han, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 17, 2025
The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic CancerJiande Han, Hanlin Yin, Taochen He, et al.
Pageof 9